David Templeton
Förmögenhet: - $ per 2026-05-31
Förmögenhet: - $ per 2026-05-31
Dr. David Templeton was previously employed as an Executive Director & Technical Director by N4 Pharma Plc, a Director-Clinical Pharmacology by Eisai Ltd. (United Kingdom), a Head-Non Clinical Development by Celltech Ltd., and a Head-Biometrics by Merck Generics Ltd.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2024-12-31 | 0 ( -.--% ) | - $ | 2026-05-31 |
| Företag | Position | Slut |
|---|---|---|
| THALIA THERAPEUTICS PLC | Ordförande | 2019-05-21 |
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Företagsledare/Principal | 2010-01-01 |
Celltech Ltd.
Celltech Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural science and engineering | Företagsledare/Principal | 2004-01-01 |
Merck Generics Ltd.
Merck Generics Ltd. Pharmaceuticals: MajorHealth Technology Provides therapies and drugs products | Företagsledare/Principal | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Celltech Ltd.
Celltech Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural science and engineering | Commercial Services |
N4 Pharma Plc
N4 Pharma Plc BiotechnologyHealth Technology Provides specialist pharmaceutical services that reformulates existing drugs and vaccines to improve their performance | Health Technology |
Merck Generics Ltd.
Merck Generics Ltd. Pharmaceuticals: MajorHealth Technology Provides therapies and drugs products | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån